Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EPS (Weighted Average and Diluted) (2019 - 2025)

Puma Biotechnology's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.26 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 35.0% year-over-year to $0.26; the TTM value through Dec 2025 reached $0.61, down 1.61%, while the annual FY2025 figure was $0.61, 1.61% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.26 in Q4 2025 per PBYI's latest filing, up from $0.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q3 2024 to a low of -$1.09 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.05, with a median of $0.08 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 1300.0% in 2023, then plummeted 433.33% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.1 in 2021, then plummeted by 230.0% to -$0.13 in 2022, then soared by 292.31% to $0.25 in 2023, then skyrocketed by 60.0% to $0.4 in 2024, then plummeted by 35.0% to $0.26 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's EPS (Weighted Average and Diluted) are $0.26 (Q4 2025), $0.17 (Q3 2025), and $0.12 (Q2 2025).